Loading stock data…
CANF
$2.93-0.26 (-8.15%)
Market ClosedLast close May 1
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Can-Fite BioPharma Ltd. in the Healthcare sector is trading at $2.93. The stock is currently near its 52-week low of $2.83, remaining 62.7% below its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why CANF maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.93
Potential Upside
5%
Whystock Fair Value$3.08
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$50.00+1606.5%
Range$50.00 – $50.00
Fundamentals
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead dru...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.95M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-201.57%
Volume
Today's trading volume
540,419
Recent News
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat
Sector Update: Health Care Stocks Lower in Friday Afternoon Trading
Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the State Street H
Top Midday Stories: Nvidia-Groq Licensing Deal; Target Attracts Growing Interest From Toms Capital
All three major US stock indexes were edging lower in midday trading on Friday following the Christm
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Investors Await Clues on Fed's Interest Rate Cut
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6% and the actively tr